The value of TOP2A, EZH2 and paxillin expression as markers of aggressive breast cancer: relationship with other prognostic factors

Introduction: The immunocytochemical expression of topoisomerase II alpha (TOP2A), enhancer of zeste homologue 2 (EZH2) and paxillin has recently gained increasing attention. Although previous studies have commented on the clinical usefulness of these markers, their role remains controversial. Aim: The purpose of the study was to investigate the expression of TOP2A, EZH2 and paxillin in relation to classic prognostic parameters and their significance as prognostic markers in imprints of resected breast carcinomas. Methods: Imprint smears from 55 patients who underwent surgical treatment for primary carcinoma in our department between 2005 and 2006 were studied immunocytochemically with the use of TOP2A, EZH2 and paxillin antibodies.Results: The expression of TOP2A correlated with higher histologic grade, tumor size and negative PR expression. High intensity staining for EZH2 expression was associated with higher histologic grade, negative ER and PR expression and positive Ki-67 expression. The expression of paxillin showed no correlation with estrogen/progesterone and HER2 expression nor with tumor grade and stage. Conclusion: Our data indicate that TOP2A and EZH2 expression are related to a more aggressive tumor phenotype. The expression of paxillin failed to correlate with any of the studied clinicopathologic factors. Further studies are needed to verify these results.

TOP2A; EZH2; Paxillin; Tumor markers; Breast cancer

[1] Nelson H.D., Tyne K., Naik A., Bougatsos C., Chan B.K., Humphrey L.: “U.S. Preventive Services Task Force. Screening for breast cancer: an update for the U.S. Preventive Services Task Force”. Ann. Intern. Med., 2009, 151, 727.

[2] Nappi O., Carrillo G.: “Prognostic and predictive factors of breast carcinoma: Beyond hormonal receptors and HER2”. Eur. J.Cancer, 2008, (suppl. 6), 1.

[3] Tang P., Skinner K.A., Hicks D.G.: “Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?”. Diagn. Mol. Pathol., 2009, 18, 125.

[4] O’Connor J.K., Hazard L.J., Avent J.M., Lee R.J., Fischbach J., Gaffney D.K.: “Topoisomerase II alpha expression correlates with diminished disease-free survival in invasive breast cancer”. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 1411.

[5] Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., Buerger H. et al.: “Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene”. Neoplasia, 2003, 5, 481.

[6] Zhu L., Li Y.F., Chen W.G., He J.R., Peng C.H., Zhu Z.G., Li H.W.: “HER2 and topoisomerase IIalpha: possible predictors of response to neoadjuvant chemotherapy for breast cancer patients”. Chin. Med. J. (Engl.), 2008, 121, 1965.

[7] Kirmizis A., Bartley S.M., Farnham P.J.: “Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy”. Mol. Cancer Ther., 2003, 2, 113.

[8] Schaller M.D.: “Paxillin: a focal adhesion-associated adaptor protein”. Oncogene, 2001, 20, 6459.

[9] Bantis A., Gianopoulos A., Gonidi M., Liossi A., Aggelonidou E., Petrakakou E. et al.: “Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value”. Cytopathology, 2004, 15, 25.

[10] Greene D.R., Taylor S.R., Wheeler T.M., Scardino P.T.: “DNA ploidy by image analysis of individuals foci of prostate cancer: apreliminary report”. Cancer Res., 1991, 51, 4084.

[11] Koss L.G., Melamed M.R., Koss L.G., Melamed M.R. (eds.): “Recognizing and classifying cells. Koss/diagnostic cytology”. 5th edition, Philadelphia, Lippincott Williams and Wilkins, 2006, 119.

[12] Werner M., Chott A., Fabiano A., Battifora H.: “Effect of formalin fixation and processing on immunohistochemistry”. Am. J. Surg., 2000, 24, 1016.

[13] Creager A.J., Geisinger K.R., Perrier N.D., Shen P., Shaw J.A., Young P.R. et al.: “Intraoperative imprint cytologic evaluation ofsentinel lymph nodes for lobular carcinoma of the breast”. Ann. Surg., 2004, 239, 61.

[14] Aihara T., Munakata S., Morino H., Takatsuka Y.: “Touch imprint cytology and immunohistochemistry for assessment of sentinel lymph nodes in patients with breast cancer”. Eur. J. Surg. Oncol., 2003, 29, 845.

[15] Aihara T., Munakata S., Morino H., Takatsuka Y.: “Comparison of frozen sections and touch imprint cytology for evaluation of sentinel lymph nodes metastasis in breast cancer”. Ann. Surg. Oncol., 2004, 11, 747.

[16] Flens M.J., van der Valk P., Tadema T.M., Huysmans A.C., Risse

E.K., van Tol G.A., Meijer C.J.: “The contribution of immunohistochemistry in diagnostic cytology. Comparisons and evaluation with immunohistochemistry”. Cancer, 1990, 65, 2704.

[17] “World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs”. Tavassoli F., Devilee P. (eds.), Lyon, IARC Press, 2003, 10.

[18] Page D.L., Anderson T.J.: “Diagnosis histopathology of the breast”. Edinburgh, Churchill Livingstone, 1987, 303.

[19] “Cytology Subgroup of the National Coordinating Committee for Breast Cancer Screening Pathology. Guidelines for cytology procedures and reporting on fine needle aspirates of the breast”. Cytopathology, 1994, 5, 316.

[20] Nielsen K.V., Ejlertsen B., Møller S., Jørgensen J.T., Knoop A., Knudsen H., Mouridsen H.T.: “The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D”. Acta Oncol., 2008, 47, 725.

[21] Genestie C., Zafrani B., Asselain B., Fourquet A., Rozan S., Validire P. et al.: “Comparison of the prognostic value of Scarff-Bloom-Richardson and Nottingham histological grades in a series of 825 cases of breast cancer: major importance of the mitotic count as a component of both grading systems”. Anticancer Res., 1998, 18, 571.

[22] Miyoshi Y., Kurosumi M., Kurebayashi J., Matsuura N., Takahashi M., Tokunaga E. et al.: “Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers” Collaborative Study Group of Scientific Research of the Japanese Breast CancerSociety. Cancer Lett., 2008, 8, 264, 44.

[23] Fritz P., Cabrera C.M., Dippon J., Gerteis A., Simon W., Aulitzky

W. E., van der Kuip: “H.c-erbB2 and topoisomerase IIalpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study”. Breast. Cancer Res., 2005, 7, R374.

[24] Pritchard K.I.: “Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer?”. J. Clin. Oncol., 2009, 27, 3875.

[25] Jacobs J.J., and van Lohuizen M.: “Polycomb repression: from cellular memory to cellular proliferation and cancer”. Biochim. Biophys. Acta, 2002, 1602, 151.

[26] Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., Buerger H., Packeisen J., Sewalt R.A., Otte A.P., van Diest P.J.: “Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene”.Neoplasia, 2003, 5, 481.

[27] Collett K., Eide G.E., Arnes J., Stefansson I.M., Eide J., Braaten A. et al.: “Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer”. Clin. Cancer Res., 2006, 12, 1168.

[28] Pietersen A.M., Horlings H.M., Hauptmann M., Langerød A., Ajouaou A., Cornelissen-Steijger P. et al.: “EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer”. Breast. Cancer Res., 2008, 10, R109.

[29] Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., Rotter V.: “Activated p53 suppresses the histone methyltransferase EZH2 gene”. Oncogene, 2004, 23, 5759.

[30] Turner C.E., Glenney J.R. Jr, Burridge K.: “Paxillin: A new vinculin-binding protein present in focal adhesions”. J. Cell. Biol., 1990, 111, 1059.

[31] Ishino K., Kaneyama, Shibanuma M., Nose K.: “Specific decrease in the level of Hic-5, a focal adhesion protein, during immortalization of mouse embryonic fibroblasts, and its association with focal adhesion kinase”. J. Cell. Biochem., 2000, 76, 411.

[32] Lipsky B.P., Beals C.R., Staunton D.E.: “Leupaxin is a novel LIM domain protein that forms a complex with PYK2”. J. Biol. Chem., 1998, 273, 11709.

[33] Brown M.C., Curtis M.S., Turner C.E., Paxillin L.D.: “Motifs may define a new family of protein recognition domains”. Nat. Struct. Biol., 1998, 5, 677.

[34] Brown M.C., Perrotta J.A., Turner C.E.: “Identification of LIM3 as the principal determinant of paxillin focal adhesion localization and characterization of a novel motif on paxillin directing vinculin and focal adhesion kinase binding”. J. Cell. Biol., 1996, 135, 1109.

[35] Schaller M.D.: “FAK and paxillin: regulators of N-cadherin adhesion and inhibitors of cell migration?”. J. Cell. Biol., 2004, 166, 157.

[36] Hagel M., George E.L., Kim A., Tamimi R., Opitz S.L., Turner

C.E. et al.: “The adaptor protein paxillin is essential fornormal development in the mouse and is a critical transducer of fibronectin signaling”. Mol. Cell. Biol., 2002, 22, 901.

[37] Yano H., Uchida H., Iwasaki T., Mukai M., Akedo H., Nakamura K. et al.: “Paxillin a and crk-associated substrate exert opposing effects on cell migration and contact inhibition of growth through tyrosine phosphorylation”. Proc. Natl. Acad. Sci., USA, 2000, 97, 9076.

[38] Vadlamudi R., Adam L., Tseng B., Costa L., Kumar R.: “Transcriptional up-regulation of paxillin expression by heregulin in human breast cancer cells”. Cancer Res., 1999, 59, 2843.

[39] Hicks D., Yoder B., Short S., Tso E., Choueiri T., Budd G. et al.: “The expression of the focal adhesion protein paxillin in breast cancer correlates with HER2 amplification and may help predict a better response to chemotherapy”. Mod. Pathol., 2005, (suppl. 1), 36A.

[40] Madan R., Smolkin M.B., Cocker R., Fayyad R., Oktay M.H.: “Focal adhesion proteins as markers of malignant transformation and prognostic indicators in breast carcinoma”. Hum. Pathol., 2006, 37, 9.